Liraglutide (Victoza) vs Semaglutide (Wegovy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline

Liraglutide (Victoza)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Semaglutide (Wegovy)

Marketed by Novo Nordisk

Approved in Atherosclerotic Cardiovascular Diseasepeptide
Reliable signal

NCT03574597 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 17,604 participants and a hard cardiovascular event primary endpoint. The primary endpoint was met: 569 participants receiving semaglutide versus 701 receiving placebo experienced a qualifying event, with a hazard ratio of 0.80 (95% CI 0.72–0.89; p<0.0001).

Reported efficacy

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)

Result source: NCT03574597

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLiraglutide (Victoza)Semaglutide (Wegovy)
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048—Not reported

LDL-C, % change

Liraglutide (Victoza)
—Not reported
Semaglutide (Wegovy)
—Not reported

Non-HDL-C, % change

Liraglutide (Victoza)
—Not reported
Semaglutide (Wegovy)
—Not reported

ApoB, % change

Liraglutide (Victoza)
—Not reported
Semaglutide (Wegovy)
—Not reported

Lp(a), % change

Liraglutide (Victoza)
—Not reported
Semaglutide (Wegovy)
—Not reported

3-point MACE (% with event)

Liraglutide (Victoza)
13% vs 14.9%−1.9 vs placebowk 260 · n 4668NCT01179048
Semaglutide (Wegovy)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Semaglutide (Wegovy)
Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 NCT03574597 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Liraglutide (Victoza): 3 of 4 rows · Semaglutide (Wegovy): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLiraglutide (Victoza)
Dropout rate
3%a
NCT01179048 · Phase 3
show 3 more results
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
10%
NCT04881110 · Phase 4 · registry result, not featured evidence
0%
NCT03010683 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01179048 · Phase 3
show 3 more results
—
NCT03260881 · Phase 4 · registry result, not featured evidence
—
NCT04881110 · Phase 4 · registry result, not featured evidence
—
NCT03010683 · Phase na · registry result, not featured evidence
Serious AEs
49.7%a
NCT01179048 · Phase 3
show 3 more results
0%
NCT03260881 · Phase 4 · registry result, not featured evidence
0%
NCT04881110 · Phase 4 · registry result, not featured evidence
0%
NCT03010683 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
nausea 11.1% (placebo 2.8%)
diarrhoea 5.7% (placebo 2.2%)
NCT01179048 · Phase 3
show 1 more result
abdominal distention 31.6%
nausea 31.6%
NCT03260881 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liraglutide (Victoza)

MACE 3-point Composite 13% (n=4668) vs 14.9% (n=4672) placebo @ 260wk
event count · % of participants
NCT01179048 · Phase 3
MACE Broad 20.3% (n=4668) vs 22.7% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
All-cause Mortality 8.2% (n=4668) vs 9.6% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Microvascular Composite 7.6% (n=4668) vs 8.9% (n=4672) placebo @ 260wk
responder rate · % of participants
NCT01179048 · Phase 3
Tcpo2 54.2 vs 43.4 placebo mmHg @ 26wk
absolute change · mmHg
NCT04881110 · Phase 4 · registry result, not featured evidence
HbA1c 6.7% (n=27) vs 6.8% (n=28) placebo @ 26wk
absolute change · percentage points
NCT04881110 · Phase 4 · registry result, not featured evidence
Fasting Glucose Change mg/dL 6.58 vs 6.49 placebo mmol/L @ 26wk
absolute change · mmol/L
NCT04881110 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 118.5 mg/dL as posted
BMI 28.7 vs 27.7 placebo kg @ 26wk
absolute change · kg
NCT04881110 · Phase 4 · registry result, not featured evidence
Waist Circumference Change 108.9 vs 104.1 placebo cm @ 26wk
absolute change · cm
NCT04881110 · Phase 4 · registry result, not featured evidence
CRP Change mg/dL 0.5 vs 0.8 placebo mg/dL @ 26wk
absolute change · mg/dL
NCT04881110 · Phase 4 · registry result, not featured evidence
Serum Creatinine Change mg/dL 1 vs 0.8 placebo mg/dL @ 26wk
absolute change · mg/dL
NCT04881110 · Phase 4 · registry result, not featured evidence
ABI 0.9 vs 1 placebo ratio @ 26wk
ratio to baseline · ratio
NCT04881110 · Phase 4 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Victoza)'s landscape · Semaglutide (Wegovy)'s landscape